ARRHYTHMIC PULSE RISK EVALUATION DEVICE, ARRHYTHMIC PULSE RISK EVALUATION SYSTEM, AND PROGRAM

摘要

[PROBLEMS] There has been conventionally a problem that the arrhythmic pulse risk of an organism such as a human being cannot be evaluated by using data collected at the early stage of drug discovery. [MEANS FOR SOLVING PROBLEMS] An arrhythmic pulse risk evaluation device comprises an animal medicinal benefit information acquiring section for acquiring animal medicinal benefit information on medicinal benefits on an animal by using a set of parameters before and after drug administration, a medicinal benefit converting section for converting the animal medicinal benefit information into object organism medicinal benefit information by using conversion source information, a cardiac muscle cell simulation section for acquiring cardiac muscle cell action information on the behavior of the cardiac muscle cells of the organism by using the object organism medicinal benefit information, an arrhythmic pulse information acquiring section for acquiring arrhythmic pulse information on the side effects of arrhythmic pulse of a drug on the heart by using the cardiac muscle cell action information, an output information construction section for constructing output information outputted by using the arrhythmic pulse information, and an output section for outputting the output information. By using data collected at the early stage of drug discovery, the arrhythmic pulse risk of an organism such as a human being can be evaluated.